Similar to SPRY4-IT1, MEG3 expression is up-regulated by 5-aza-CdR treatment, indicating that reduced MEG3 levels in gastric cancer cells could be partly due to hypermethylation of the IG-DMR of the MEG3 gene [94]. The gene discussed is HAUS3; the disease is gastric cancer.